Two new position papers convincingly propose that nonalcoholic fatty liver disease needs a new name — metabolic associated fatty liver disease (MAFLD). A new name for this disease affecting nearly one billion people globally is overdue, as knowledge gained from the past decades has assuringly demonstrated that MAFLD is a purely metabolic disorder.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Transition patterns of metabolic dysfunction-associated fatty liver disease status in relation to arterial stiffness progression: a health check-up cohort study
Scientific Reports Open Access 15 June 2023
-
NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care
Internal and Emergency Medicine Open Access 17 February 2023
-
A comparison of NAFLD and MAFLD diagnostic criteria in contemporary urban healthy adults in China: a cross-sectional study
BMC Gastroenterology Open Access 19 November 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Ludwig, J., Viggiano, T. R., McGill, D. B. & Oh, B. J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 55, 434–438 (1980).
Fleming, K. A. et al. Mallory bodies in alcoholic and non-alcoholic liver disease contain a common antigenic determinant. Gut 22, 341–344 (1981).
Beringer, A. & Thaler, H. Relationships between diabetes mellitus and fatty liver [German]. Dtsch. Med. Wochenschr. 95, 836–838 (1970).
Day, C. P. & James, O. F. Steatohepatitis: a tale of two “hits”? Gastroenterology 114, 842–845 (1998).
Marchesini, G. et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med. 107, 450–455 (1999).
Marchesini, G. et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50, 1844–1850 (2001).
Eslam, M. et al. A new definition for metabolic associated fatty liver disease: an international expert consensus statement. J. Hepatol. https://doi.org/10.1016/j.jhep.2020.03.039 (2020).
Eslam, M., Sanyal, A. J. & George, J. International Consensus Panel MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology https://doi.org/10.1053/j.gastro.2019.11.312 (2020).
Tilg, H., Zmora, N., Adolph, T. E. & Elinav, E. The intestinal microbiota fuelling metabolic inflammation. Nat. Rev. Immunol. 20, 40–54 (2020).
Angulo, P. et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver dmetaisease. Gastroenterology 149, 389–397 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Tilg, H., Effenberger, M. From NAFLD to MAFLD: when pathophysiology succeeds. Nat Rev Gastroenterol Hepatol 17, 387–388 (2020). https://doi.org/10.1038/s41575-020-0316-6
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-020-0316-6
This article is cited by
-
Transition patterns of metabolic dysfunction-associated fatty liver disease status in relation to arterial stiffness progression: a health check-up cohort study
Scientific Reports (2023)
-
NAFLD as the metabolic hallmark of obesity
Internal and Emergency Medicine (2023)
-
New predictive models and indices for screening MAFLD in school-aged overweight/obese children
European Journal of Pediatrics (2023)
-
NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care
Internal and Emergency Medicine (2023)
-
An international multidisciplinary consensus statement on MAFLD and the risk of CVD
Hepatology International (2023)